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The growth inhibitory effects of medroxyprogesterone acetate (MPA) and tamoxifen 
(TAM) were tested on three long-established endometrial carcinoma cell lines (HEC-1, 
KLE, and RL95-2) and on UM-EC-l, a new endometrial carcinoma cell line established 
in our laboratory. MPA and TAM were used in growth experiments either alone, simul- 
taneously, or sequentially. The MCF-7 breast cancer cell line was used as a control. None 
of the endometrial carcinoma cell lines showed significant sensitivity to 0.1-10 PM MPA. 
In contrast, 10 days exposure to 5 PM TAM induced 83 and 70% growth inhibition in 
HEC-1 and KLE cultures, whereas the growth of UM-EC-1 was inhibited by 99.7% and 
RL95-2 cultures by 100%. TAM-induced growth inhibition was reversible since all cell 
lines resumed logarithmic growth when TAM was removed from the culture medium. 
Addition of 17-/3-estradiol (EJ to the culture medium did not accelerate recovery, and 
reversal of TAM-induced growth inhibition was not seen when TAM and E, were added 
simultaneously. This is consistent with our finding that, except for MCF-7, these cell lines 
did not show detectable estrogen receptor (ER) activity in assays performed at the time 
of these experiments. When treated sequentially with TAM and MPA, all cell lines resumed 
logarithmic growth when medium containing TAM was replaced with medium containing 
MPA. Simultaneous exposure to 5 pM MPA and 5 pM TAM resulted in a slight additive 
growth inhibitory effects only in KLE cultures. Our results show that MPA does not have 
growth inhibitory effects in these endometrial carcinoma cell cultures, whereas TAM exerts 
a potent growth inhibitory effect that is not reversed by estrogen and may thus be mediated 
through a mechanism different from blockade of ER. In vitro results with the UM-EC-l 
cell line correlated with the clinical response of the cell line donor. Her disease progressed 
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during postoperative MPA therapy, but subsequently she responded to TAM therapy. 
0 1988 Academic Press, Inc. 
INTRODUCTION 
Medroxyprogesterone acetate (MPA) is one of the most commonly used hormonal 
agents for the treatment of advanced or recurrent endometrial adenocarcinoma, 
with a response rate of 30 to 35% [1,2]. Of the progesterone receptor (PgR)- 
positive tumors, 82-83% have been reported to respond to MPA therapy both 
in viva [3] and in vitro [4]. However, the PgR content of endometrial carcinoma 
varies directly to the degree of differentiation [5-71 and inversely with stage of 
the tumor [7]. Thus one would predict that MPA therapy would be less effective 
in advanced and poorly differentiated tumors. In addition, MPA has been shown 
to reduce PgR content of both normal [8] and malignant endometrial cells 19,101, 
which could result in loss of hormone responsiveness. Tamoxifen (TAM), a 
nonsteroidal antiestrogen which is often used in breast cancer therapy, has also 
been used occasionally in the treatment of patients with advanced and recurrent 
endometrial carcinoma [l l-161. TAM is known to have some estrogenic effects 
at low concentration and one of these effects is induction of PgR both in normal 
[ 171 and malignant endometrium [ 18-201. This property has focused interest on 
sequential or simultaneous use of TAM and MPA in the therapy of endometrial 
carcinoma. Zaino et al. [21] have shown greater regression of nude mouse tumors 
with sequential use of TAM and MPA than could be obtained with MPA alone. 
However, in the few clinical trials performed, simultaneous and sequential use 
of these agents has not been shown to increase the response rate over that 
achieved with MPA alone [15,19,22]. 
Using cell cultures, we examined the direct growth inhibitory effect of these 
agents on endometrial carcinoma cells. This was accomplished by exposing log- 
arithmically growing cell cultures to MPA and TAM. Simultaneous and sequential 
treatment of the cells with these agents was also studied. In addition to three 
long-established cell lines obtained from other laboratories, we studied a new 
cell line recently established in our laboratory. The in vitro sensitivity of this 
cell line was compared with the clinical response of its donor. 
MATERIALS AND METHODS 
Cell lines. The long-established endometrial cancer cell lines used in this study 
were obtained from the American Type Culture Collection (Rockville, MD). The 
HEC-1 cell line was established by Kuramoto et al. in 1972 from a moderately 
differentiated papillary endometrial adenocarcinoma [23]. KLE was established 
in 1984 by Richardson et al. from a poorly differentiated adenocarcinoma [24], 
and RL95-2 was established by Way et al. in 1983 from a moderately differentiated 
papillary adenocarcinoma [25]. The UM-EC-l cell line was recently established 
in our laboratory from a poorly differentiated endometrial adenocarcinoma [26]. 
The MCF-7 breast cancer cell line established by Soule et al. in 1973, from 
metastatic cells in pleural effusion [27], was obtained from Dr. C. McGrath of 
the Michigan Cancer Foundation. 
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At least two studies of the estrogen receptor (ER) content of the HEC-1 cell 
line have been reported since the line was established. Shapira et al. [28] were 
not able to demonstrate specific estrogen binding in these cells, but Satyaswaroop 
et al. [29] found low levels of ER (10 fmole/mg protein) in HEC-1 cells. The 
KLE cell line was reported to contain varying amounts of cytosolic ER (25-300 
fmole/mg protein) when it was tested at different passages during establishment 
of the cell line. Similarly, RL95-2 cells were reported to have both cytosolic 
(10.5 fmole/mg protein) and nuclear (1020 + 230 fmole/mg DNA) ER when the 
cell line was first established in culture. The progesterone receptor content of 
these cell lines was not described in these reports. The MCF-7 cell line has been 
demonstrated to contain both ER and PgR, but subpopulations of this cell line 
lacking ER have also been reported [30,31]. 
The donor of UM-EC-Z. The donor of UM-EC-1 cell line is a 66-year-old white 
female who underwent hysterectomy, bilateral salpingo-oophorectomy, lymph 
node biopsy, and liver cyst aspiration for endometrial carcinoma in June 1986. 
On histological evaluation the tumor revealed involvement of the cervix, the 
outer third of the myometrium, and the paraaortic lymph nodes. Cytologic evaluation 
of the fluid aspirated from a 2 x 2-cm cyst in the liver revealed cells consistent 
with primary tumor. 
Steroid receptor assays. Steroid receptor content of the cell lines used in this 
study was tested in two different laboratories using the dextran-charcoal method 
as described previously [32]. Cells were grown to confluence in 75cm* culture 
flasks in Dulbecco’s minimum essential medium (DMEM) containing 1% (v/v) 
nonessential amino acids, 2 mM L-glutamine, 100 u/ml penicillin, and 100 pg/ml 
streptomycin (DMEM +). DMEM+ was supplemented with 15% fetal bovine 
serum (FBS) except as noted. 
Three to five days before harvest, the cells were fed with DMEM + containing 
5% dextran coated charcoal-treated FBS (DS medium). On the last day before 
harvest, the cultures were fed with Ham’s F-12 medium. The cells were harvested 
by trypsinization and sedimented by centrifugation, and cell pellets of at least 
500 mg (wet wt) were immediately frozen and stored in liquid nitrogen until the 
assays were performed. The steroid receptor content of each of the long-established 
cell lines was assayed twice. UM-EC-1 cells were tested in six different assays 
using cells ranging from passage 4 to 35. For one assay cells were grown in 480- 
cm* roller bottles by the method described above and in one experiment a nude 
mouse tumor induced by UM-EC-1 cells was tested. 
Cell growth experiments. Cell growth experiments were performed as described 
previously [33]. Cells were cultured in 6-well plastic plates and allowed to grow 
for 3 days to reach the logarithmic growth phase. Thereafter, the medium and 
the drugs were replaced daily to ensure that nutrient depletion would not be a 
factor affecting cell growth and that fresh and effective drug was present each 
day during the entire experiment. 
Drug preparation. Tamoxifen citrate was generously provided by Len-as-Medica 
Pharmaceuticals, Huhtamaki Oy, Turku, Finland. It was dissolved in 70% ethanol 
at 1000 times the highest final concentration used for experiments and stored as 
stock solutions at -20°C until used. I7-P-Estradiol (E’) and 6-a-methyl-17 -a- 
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FIG. 1. Effect of medroxyprogesterone acetate (MPA) on the growth of endometrial carcinoma 
cells in culture. Cells were plated and allowed to grow for 3 to 4 days in D5 medium and then were 
fed daily with D5 medium containing the indicated concentrations of MPA. Three replicate wells 
were counted on each of the days indicated. 
hydroxyprogesterone acetate (Sigma) were dissolved in absolute ethanol and 
diluted to the appropriate final concentration with culture medium. In drug-treated 
and control cultures the final concentration of ethanol was always less than 0.1%. 
Ethanol at 0.1% or less does not effect growth rate, viability, or saturation density 
of the cultured cells [34]. 
RESULTS 
Steroid Receptor Content 
Steroid hormone receptors were not detected in any of the long-established 
endometrial carcinoma cell lines. In UM-EC-l low amounts of ER (6.5 fmole/mg 
protein) and PgR (22 fmole/mg protein) could be demonstrated only in one of 
the six assays. For this assay, cells from the fourth passage grown in roller 
bottles were used. In addition, the UM-EC-1 nude mouse tumor contained barely 
detectable levels of ER activity (1.5 fmole/mg protein). No PgR binding was 
found in this specimen. As expected, MCF-7 cells were found to contain high 
but variable levels of both ER (105-454 fmole/mg protein) and PgR 21-120 
fmole/mg protein) in repeated assays. 
Effects of MPA Alone on Cell Growth 
The effect of MPA on the growth of the endometrial carcinoma cell lines is 
presented in Fig. 1. Even with the highest MPA concentration tested (10 PM), 
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FIG. 2. Effects of daily feeding with tamoxifen on cell growth in endometrial carcinoma and 
MCF-7 cell lines. Cells were allowed to grow in D, medium for 3 days and then were fed daily with 
D, containing the indicated concentrations of tamoxifen. Replicate wells were counted on the days 
indicated. 5 pM TAM is indicated with an arrow. 
only 27-30% reduction in cell number was achieved after 10 days of exposure 
to the drug. When the same concentration of MPA was present in the medium 
of MCF-7 cells, the cell number was reduced by 68% compared to control (data 
not shown). 
Effects of TAM Alone on Cell Growth 
The results of a dose-response experiment showing the growth inhibitory effect 
of TAM on the four endometrial carcinoma cell lines and MCF-7 are presented 
in Fig. 2. Since 5 pM TAM was capable of inducing a cytostatic effect in MCF- 
7 and also caused growth inhibition in all of the endometrial cancer cell lines, 
this concentration of TAM (marked with arrows in Fig. 2) was used in subsequent 
experiments. Ten days of feeding with 5 pM TAM produced a 93% reduction 
in cell number in MCF-7, an 83% reduction in HEC-1, and a 70% reduction in 
KLE cultures. In UM-EC-1 cultures a 99.7% reduction in cell growth was seen 
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FIG. 3. Reversal of tamoxifen-induced growth inhibition in endometrial carcinoma cell lines is 
shown. Tamoxifen (5 PM) was added to cultures starting from Day 2 or 3. After 3 to 5 days of daily 
feeding with tamoxifen, the medium was removed from the wells and the cultures were fed with 
medium containing estradiol (EJ, D, medium (D5), tamoxifen plus estradiol (T + E,), or were 
continued in tamoxifen alone (T). Tamoxifen and estradiol were used in a ratio of 50: 1. Control 
cultures grown in D, medium are indicated by the symbol C. 
and no viable cells remained in RL95-2 cultures after 10 days of feeding with 5 
pM TAM. 
Reversibility of TAM-induced Growth Inhibition 
In MCF-7 cultures TAM-induced growth inhibition has been shown to be 
partially reversed by simultaneous use of E2, and E2 has been shown to increase 
the rate of recovery from TAM blockade [31,33,34]. We examined whether E2 
would have the same effect in these endomentrial carcinoma cell line cultures. 
The results of this experiment are presented in Fig. 3. 
After 3 to 5 days of feeding with 5 pM TAM, all cell lines resumed logarithmic 
growth when the drug was removed from the culture. The cells recovered equally 
well in the presence or absence of 0.1 pM E2 (50: 1 ratio of TAM to E2). When 
TAM was replaced by medium containing both TAM and E2 (in a ratio of 50: 1) 
in KLE, HEC-1, and UM-EC-1 cultures, the growth inhibitory effect remained 
the same as in cultures fed with TAM alone. In RL95-2 cultures, the growth 
inhibitory effect of TAM appeared to be partially blocked by E,. However, in 
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FIG. 4. Growth curves demonstrating the effect of 5 pM TAM and 5 pM MPA given sequentially 
or simultaneously on the growth of endometrial carcinoma cells in virro. Cells were allowed to grown 
in D, medium for 3 days and then were fed daily with DS medium containing the indicated combinations 
of drugs. A indicates the use of TAM followed by MPA. 
a subsequent experiment when these cells were fed with medium containing 5 
PM TAM and 1 PM E2 (in a ratio of 5: l), reversal of TAM-induced growth 
inhibition could not be demonstrated. 
Simultaneous and Sequential Use of TAM and MPA 
To test the effects of the combination of TAM and MPA, these agents were 
administered simultaneously or sequentially to logarithmically growing cells. Results 
are presented in Fig. 4. In UM-EC-l cultures, simultaneous exposure to 5 ,uM 
TAM and 5 PM MPA resulted in partial reversal of the TAM-induced growth 
inhibition, thus showing an antagonist effect of the two drugs. In RL95-2 and 
HEC-1 cultures, simultaneous use of these drugs had the same effect as TAM 
alone, whereas in KLE cultures a slight additive growth inhibitory effect was 
observed. All four endometrial carcinoma cell lines resumed logarithmic growth 
when medium containing TAM was replaced with medium containing MPA. Thus 
TAM did not increase the sensitivity of these cells to MPA. However, in KLE 
cultures recovery of logarithmic growth under these conditions was slower than 
that in the other endometrial carcinoma cultures. 
Effects of Postoperative Hormone Therapy in the Donor of UM-EC-I 
Postoperatively the donor of the UM-EC-1 cell line was given 160 mg MPA/day 
for 6 weeks. During that time, vaginal cuff recurrence and pelvic node enlargement 
246 GRENMAN ET AL. 
on CT scan were noted. The vaginal cuff recurrence was treated with a radioactive 
cesium implant. MPA was discontinued and the patient was given 40 mg TAM 
per day. She began to show clinical improvement and resumed normal activities. 
She has had no evidence of disease for 6 months. A CT scan of the abdomen 
after 23 weeks of TAM treatment showed resolution of the pelvic nodal disease 
seen on the first CT scan. However, a mass was detected on this scan in the 
lower paraaortic region. The suboptimal quality of the first CT scan of the 
paraaortic region made it impossible to evaluate the tumor response in this area. 
DISCUSSION 
MPA has an established role in the therapy of advanced and metastatic en- 
dometrial carcinoma, The therapeutic value of TAM in these cases is not well 
established since in most studies it has been used as second-line chemotherapy 
for heavily pretreated patients and few controlled trials have been performed 
[ll-161. 
The mechanisms by which these hormonal agents exert growth inhibitory 
effects are under debate. The effects observed in vivo can be the result of either 
the direct effects of these agents on the tumor or the more indirect actions 
mediated through changes in the levels of circulating hormones. MPA is known 
to reduce circulating estrogen levels, to increase clearance of testosterone, and, 
consequently, to decrease conversion of androgens to estrogens [35]. MPA also 
has a high affinity for the PgR and it has been shown to reduce the PgR content 
of both normal [8] and malignant endometrial cells [9,10]. A good correlation 
has been shown between the PgR level in tumor tissue and the response to 
progestogens, with 82% responding when PgR is positive [3,41 and only 11% 
when PgR is negative [3]. TAM has a complex mixture of estrogenic and an- 
tiestrogenic effects depending on the biological system, species, and concentration 
of the drug [21,36-381. In vitro studies with breast cancer cell lines have shown 
that estrogen antagonism of TAM is mediated, at least in part, through estrogen 
receptor binding [3 1,39,40], but there is also evidence of a specific antiestrogen 
binding site (AEBS) that is distinct from the ER [40-421. 
The use of TAM as a chemotherapeutic agent in the treatment of endometrial 
adenocarcinoma has given mixed results. In a pilot study, Swenerton et al. [ 1 l] 
reported a response to TAM in 4 of 7 patients studied. Similarly, Bonte et al. 
achieved complete regression in 2 and partial regression in 7 of 17 patients treated 
with TAM as a second-line therapy [12]. However, in a study performed by the 
Gynecologic Oncology Group, no tumor regression occurred in 17 patients with 
endometrial adenocarcinoma. Nevertheless, 11 patients had stable disease for 
8-48 weeks, although the remaining 6 patients showed progression of the disease. 
In the same study, of the 5 patients with adenosquamous carcinoma of the 
endometrium, 2 had stable disease for 4 and 16 weeks, and 3 experienced progression 
[141. Unfortunately it is not possible to judge the therapeutic value of TAM from 
these studies in which the drug was used as palliative treatment. In spite of this, 
the rather striking clinical responses observed in several patients stand out. 
We studied the direct growth inhibitory effects of MPA and TAM on four 
endometrial carcinoma cell lines. When the cells were exposed to 0.1 and 1 pM 
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MPA, no growth inhibitory effect was seen and at 10 ,uM MPA concentration 
only 30% growth inhibition was observed. Our findings are in accordance with 
the results of Satyaswaroop et al. [43] and Ishiwata et al. [44], who have shown 
MPA-induced growth inhibition in endometrial carcinoma cell cultures only at 
very high concentrations. On the other hand, it is to be noted that consistent 
detectable PgR activity was not found in any of these endometrial carcinoma 
cell lines. MCF-7 cells which have more stable expression of PgR activity were 
inhibited by 10 ,xLM MPA. 
The TAM concentrations used in this study are of the same magnitude as 
those used in previous studies dealing with TAM-induced growth inhibition in 
breast cancer cell cultures [31,39,40,42]. In all cell lines we found clear, dose- 
dependent TAM-induced effects on cell growth and viability which varied from 
70% growth inhibition to complete cell kill after 10 days of feeding with 5 PM 
TAM. When a 1 PM TAM concentration was used, no growth inhibition was 
observed, which is in accordance with the results of Holinka et al. who used 1 
pM TAM in Ishikawa cell cultures [45]. 
In in vitro studies with breast cancer cell lines, three distinct effects of TAM 
have been demonstrated. These include both estrogen-reversible and estrogen- 
irreversible growth inhibitory effects and what has been termed the direct cytotoxic 
effect of TAM [40,42]. TAM-inhibited MCF-7 cultures have been shown to 
recover faster in the presence of E2 than in medium alone [33,34,46]. Furthermore, 
simultaneous use of TAM and EZ results in partial reversal of growth inhibition 
[31,33,34,42,46]. In the experiments reported herein using endometrial carcinoma 
cell lines, no competitive effects of TAM and E2 were noted. The endometrial 
carcinoma cells recovered from TAM-induced growth inhibition equally well in 
both the presence and absence of E,, and simultaneous exposure of the cells to 
TAM and E2 did not reduce the growth inhibitory effect of the TAM. These 
results are very similar to those we obtained previously with cervical carcinoma 
cells [33] and with some, but not all, squamous cell carcinomas of the head and 
neck region [34,46]. In those experiments, TAM was shown to have a dose- 
dependent, estrogen-irreversible growth inhibitory effect on certain cell lines. 
Taken together, our present findings and some of our earlier results indicate that 
in some cancer cell types TAM has a potent growth-regulating effect that is 
independent of the action mediated through the ER. 
Progestins are known to decrease PgR content of cells which may reduce the 
drug’s inhibitory effect and allow primarily responsive tumors to escape therapy 
[9,10]. In contrast, in both clinical [l&20] and nude mouse [20,37] studies TAM 
has been shown to increase the PgR content of endometrial carcinoma tissue. 
However, in clinical trials sequential or simultaneous administration of MPA and 
TAM has not been superior to that of MPA alone [ 15,19,22]. 
We were not able to increase the sensitivity of endometrial carcinoma cell 
lines to MPA by either simultaneous or sequential combinations of TAM and 
MPA in three of four endometrial carcinoma cell cultures. KLE cells did appear 
to have a slight increase in growth inhibition with simultaneous administration 
of the drugs. This was the only line which retained susceptibility to MPA alone, 
a finding that is compatible with the two agents working by different mechanisms. 
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In contrast, in UM-EC-1 cultures simultaneous use of these drugs resulted in 
partial reversal of the TAM-induced growth inhibition. The mechanism responsible 
for this finding remains unclear, but could be the result of competition for a 
single receptor if both drugs do not have the same effect on that receptor. 
In the case of UM-EC-l we had an opportunity to compare the clinical response 
of the patient with the in vitro response achieved with MPA and TAM. We were 
not able to demonstrate significant growth inhibition in UM-EC-1 cultures even 
with 10 pM MPA and correspondingly the disease progressed in the patient 
during 6 weeks of postoperative therapy with MPA. In contrast, UM-EC-l was 
very sensitive to 5 pM TAM in vitro and in the patient at least a partial regression 
of lymphatic disease occurred with moderately high-dose TAM treatment. Thus 
there was a good correlation between the in vitro and in vivo responses. 
Our data from this study and from our previous studies with cervical carcinoma 
and head and neck carcinoma cultures indicate that the in vitro growth inhibitory 
effect of TAM can be demonstrated in ER-negative cell lines and appears to be 
mediated through a mechanism different from blockade of high-affinity ER. Fur- 
thermore, in this study TAM has been shown to have potent growth inhibitory 
effects on progesterone receptor-negative and therefore MPA-resistant endometrial 
carcinoma cells. These findings are of special importance since patients who are 
most likely to need adjuvant therapy for advanced or recurrent endometrial 
carcinoma are those with ER- and PgR-negative tumors. Randomized controlled 
studies of the use of high-dose TAM as a first-line chemotherapeutic agent in 
poorly differentiated endometrial carcinoma should be considered. 
Note added in proof. 
Since the completion of this manuscript a new cell line, UM-EC-2, has been established from 
another patient with MPA-resistant, advanced, poorly differentiated endometrial carcinoma. UM- 
EC-2, like the cell lines described in this paper, is very sensitive to growth regulation by tamoxifen. 
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